Patients are eligible for participation with ECOG performance status 0-2 as many patients have experienced substantial weight loss at oesophageal cancer diagnosis, and single agent PD1/PDL1 inhibition is better tolerated than platinum-based chemotherapy [27]. The gene discussed is CD274; the disease is carcinoma of esophagus.